Clinical observation of siwu decoction in the treatment of xerosis pruritus

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100052190

Enrollment

Unknown

Registered

2021-10-22

Start date

2022-03-01

Completion date

Unknown

Last updated

2022-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

xerosis

Interventions

Observation group:Siwu Decoction

Control group:Ebastine tablets

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria for xeroderma pruritus; 2. Clear consciousness and normal perception; 3. Those who voluntarily joined the trial and signed the "informed consent form".

Exclusion criteria

Exclusion criteria: 1. Combined with other skin diseases, those who need local or systemic treatment with other drugs; 2. Those who are using topical steroids, antibiotics, antifungal drugs, oral antihistamines, and immunomodulatory drugs; 3. Combined with severe heart and renal failure, malignant tumor; 4. Those who are allergic to the drugs used in the treatment of this program; 5. Pregnant women, lactating women and those who are planning to have children in the near future.

Design outcomes

Primary

Measure	Time frame
Pruritus severity;Recurrence rate;	—

Secondary

Measure	Time frame
stratum corneum hydration;transepidermal water loss;pH value;	—

Countries

China

Contacts

Public ContactXu Huiwen

Yangzhou University School of Nursing

1084226902@qq.com+86 18168660126

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026